Phiphatpatthamaamphan Kittichet, Vilaichone Ratha-Korn, Siramolpiwat Sith, Tangaroonsanti Anupong, Chonprasertsuk Soonthorn, Bhanthumkomol Patommatat, Pornthisarn Bubpha, Mahachai Varocha
Gastroenterology Unit, Thammasat University Hospital, Pathumthani, Thailand E-mail :
Asian Pac J Cancer Prev. 2016;17(4):1903-7. doi: 10.7314/apjcp.2016.17.4.1903.
Studies of effects of IL-1 polymorphisms, CYP2C19 genotype together with antibiotic resistance for H. pylori eradication are rare worldwide. The present study was designed to evaluate efficacy of 10-day sequential therapy (SQT) and 14-day standard triple therapy (STT) with four- times-daily dosing of amoxicillin for H. pylori eradication related to these important host and bacterial factors in Thailand.
This prospective randomized study was performed during March 2015 to January 2016. H. pylori infected gastritis patients were randomized to receive 10-day sequential therapy and 14-day standard triple therapy. CYP2C19 genotyping, IL1 polymorphism (IL-1B and IL-1RN genotypes) and antibiotic susceptibility tests were performed in all patients. 13C-UBT was conducted to confirm H. pylori eradication at least 4 weeks after treatment.
A total of 100 patients (33 males and 67 females, mean age=51.1 years) were enrolled. Eradication rate by PP analysis was 97.9% (47/48) with the 10-day SQT regimen and 87.8% (43/49) with 14-day STT regimen (97.9% vs 87.8%; p-value=0.053). Antibiotic susceptibility testing demonstrated 45% resistance to metronidazole, 14.8% to clarithromycin, and 24.1% to levofloxacin. CYP2C19 genotyping revealed 44.9% RM, 49% IM and 6.1% PM. IL-1B and IL-1RN genotypes were demonstrated as 21.4% for CC, 48.1% for TC, 36.8% for TT, 72.7% for 1/1, and 21.2% for 1/2 genotypes, respectively. The 10-day SQT regimen provided 100% eradication in patients with clarithromycin or dual clarithromycin and levofloxacin H. pylori resistant strains. Moreover, the 10-day SQT regimen resulted in a 100% eradication rate in all patients with CYP2C19 genotype RM and almost type of IL-1B (TC and TT) and IL1-RN genotypes ( 1/2 and other).
Treatment with 10-day sequential therapy is highly effective for H. pylori eradication regardless of the effects of clarithromycin resistance, dual clarithromycin and levofloxacin resistance, CYP2C19 genotype, IL-1B and IL1-RN genetic polymorphisms and can be used as effective first line therapy in Thailand.
白细胞介素-1(IL-1)基因多态性、细胞色素P450 2C19(CYP2C19)基因型以及抗生素耐药性对幽门螺杆菌根除影响的研究在全球范围内都很罕见。本研究旨在评估在泰国,每日四次服用阿莫西林的10天序贯疗法(SQT)和14天标准三联疗法(STT)对幽门螺杆菌根除的疗效,该疗效与这些重要的宿主和细菌因素相关。
这项前瞻性随机研究于2015年3月至2016年1月进行。幽门螺杆菌感染的胃炎患者被随机分为接受10天序贯疗法和14天标准三联疗法。对所有患者进行CYP2C19基因分型、IL-1基因多态性(IL-1B和IL-1RN基因型)以及抗生素敏感性测试。治疗后至少4周进行13C-尿素呼气试验(13C-UBT)以确认幽门螺杆菌根除情况。
共纳入100例患者(33例男性和67例女性,平均年龄=51.1岁)。按符合方案(PP)分析,10天SQT方案的根除率为97.9%(47/48),14天STT方案的根除率为87.8%(43/49)(97.9%对87.8%;p值=0.053)。抗生素敏感性测试显示,对甲硝唑耐药率为45%,对克拉霉素耐药率为14.8%,对左氧氟沙星耐药率为24.1%。CYP2C19基因分型显示,快速代谢型(RM)占44.9%,中间代谢型(IM)占49%,慢代谢型(PM)占6.1%。IL-1B和IL-1RN基因型中,CC基因型占21.4%,TC基因型占48.1%,TT基因型占36.8%,1/1基因型占72.7%,1/2基因型占21.2%。10天SQT方案对克拉霉素或克拉霉素与左氧氟沙星双重耐药的幽门螺杆菌菌株患者的根除率为100%。此外,10天SQT方案对所有CYP2C19基因型为RM以及几乎所有IL-1B(TC和TT)和IL-1RN基因型(1/2及其他)的患者的根除率均为100%。
无论克拉霉素耐药、克拉霉素与左氧氟沙星双重耐药、CYP2C19基因型、IL-1B和IL-1RN基因多态性的影响如何,10天序贯疗法治疗幽门螺杆菌根除效果显著,可作为泰国有效的一线治疗方法。